October 17, 2025

PHOENIX fördert Forschung: Pharmazie Wissenschaftspreis für Pharmazeutische Technologie verliehen

PHOENIX fördert Forschung: Pharmazie Wissenschaftspreis für Pharmazeutische Technologie verliehen

Herzlichen Glückwunsch an JunProf. Dr. Philipp Uhl von der Universität Heidelberg und sein Team. Für PHOENIX ist das eine ganz besondere Auszeichnung, denn als approbierter Apotheker mit Schwerpunkt in der pharmazeutischen Forschung verbindet Philipp Uhl Praxis und Forschung – genau das, was die pharmazeutische Versorgung von morgen braucht.

Die Forschung des Teams könnte die Arzneimitteltherapie verändern: Sie haben eine Methode entwickelt, mit der empfindliche Wirkstoffe künftig als Tablette statt Spritze verabreicht werden können – ein großer Vorteil für viele Patientinnen und Patienten.

Der PHOENIX Pharmazie Wissenschaftspreis fördert genau solche Innovationen. Denn unser Motto „Wir bringen Gesundheit“ bedeutet für uns nicht nur Arzneimittel zu liefern, sondern auch die Unterstützung von Forschung, die die Versorgung von morgen sichert.

PHOENIX vergibt den Wissenschaftspreis in vier Kategorien. Der Preis ist mit insgesamt 40.000 € dotiert. Er würdigt damit pharmazeutische Spitzenforschung in Deutschland, Österreich und der Schweiz.

Die Preisverleihung fand an der Universität Heidelberg statt – das Forschungsteam nahm die Trophäe mit großer Freude entgegen.

Our latest News

discover more
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

New AI System Provides Treatment Recommendations for Complex Blood Cancers

New AI System Provides Treatment Recommendations for Complex Blood Cancers

Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and the Heidelberg University Hospital (UKHD) have developed “HemaGuide,” an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has shown a high degree of agreement with the recommendations of experienced experts and could significantly improve […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp